Telaprevir in the treatment of acute hepatitis c virus infection in HIV-infected men

Clinical Infectious Diseases

Volumn 58, Issue 6, 2014, Pages 873-879

  Fierer, Daniel S ^a   Dieterich, Douglas T ^b   Mullen, Michael P ^a   Branch, Andrea D ^b   Uriel, Alison J ^b   Carriero, Damaris C ^b   Van Seggelen, Wouter O ^a   Hijdra, Rosanne M ^a   Cassagnol, David G ^a   Akil, Bisher ^c   Bailey, Juan ^c   Bellman, Paul ^c   Bowers, Daniel ^c   Bungay, Krisczar ^c   Burger, Susanne ^c   Carpenter, Ward ^c   Chavez, Robert ^c   Chow, Rita ^c   Cohen, Robert ^c   Dalton, Patrick ^c   Dellosso, John ^c   Demidont, Adrian ^c   Dillon, Stephen ^c   Donlon, Eileen ^c   Farrow, Terry ^c   Gardenier, Donald ^c   Guadron, Rodolfo ^c   Haber, Stuart ^c   Higgins, Lawrence ^c   Hitzeman, Lawrence ^c   Hsu, Ricky ^c   Huprikar, Shirish ^c   Inada, Victor ^c   Jacob, Sneha ^c   Johnson, Livette ^c   Johnston, Barbara ^c   Kaminsky, Donald ^c   Klein, Oscar ^c   Kwong, Jeffrey ^c   Lares Guia, Jose ^c   Leach, Eric ^c   Levine, Randy ^c   Linetskaya, Irina ^c   Litvinova, Larisa ^c   Malhotra, Amisha ^c   Mandell, William ^c   Markowitz, Martin ^c   Mayer, Gal ^c   Meraz, Eddie ^c   Mortensen, Erik ^c   Ng, Michel ^c   Olivieri, Joseph ^c   Paolino, Charles ^c   Photangtham, Punyadech ^c   Psevdos, George ^c   Radix, Anita ^c   Rapaport, Steven ^c   Rodriguez Caprio, Gabriela ^c   Shay, William ^c   Somasundaram, Nirupama ^c   Sorra, Lembitu ^c   Stivala, Alicia ^c   Tran, Richie ^c   Urbina, Antonio ^c   Vail, Rona ^c   Wallach, Francis ^c   Wang, Wen ^c   Weiss, Susan ^c   Wiener, Melissa ^c   more..

^a Division of Infectious Diseases   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

acute HCV; HIV infection; men who have sex with men; telaprevir; treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; HEMOGLOBIN; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT; OLIGOPEPTIDE;

ACUTE HEPATITIS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE CLEARANCE; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; HAND PARESTHESIA; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HERPES ZOSTER; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIDDLE AGED; PILOT STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REINFECTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN ABSCESS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; CLINICAL TRIAL; DRUG COMBINATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE HOMOSEXUALITY; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PILOT PROJECTS;

EID: 84895755435     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit799     Document Type: Article

References (41)

1. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31: 1090-101.
2. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452-7.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
4. Gilleece YC, Browne RE, Asboe D, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 2005; 40:41-6.
5. Luetkemeyer A, Hare CB, Stansell J, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41:31-6.
6. Dominguez S, Ghosn J, Valantin MA, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006; 20:1157-61.
7. Vogel M, Nattermann J, Baumgarten A, et al. Pegylated interferon-alfa for the treatment of sexually transmitted acute hepatitis C in HIVinfected individuals. Antivir Ther 2006; 11:1097-101.
8. Matthews GV, Hellard M, Haber P, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009; 48:650-8.
9. Schnuriger A, Dominguez S, Guiguet M, et al. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS 2009; 23: 2079-89.
10. Piroth L, Larsen C, Binquet C, et al. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology 2010; 52:1915-21.
11. Lambers FA, Brinkman K, Schinkel J, et al. Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration. AIDS 2011; 25:1333-6.
12. Obermeier M, Ingiliz P, Weitner L, et al. Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): the "real-life setting" proves the concept. Eur J Med Res 2011; 16:237-42.
13. Thomson EC, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 2011; 60:837-45.
14. Garg S, Taylor LE, Grasso C, Mayer KH. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. Clin Infect Dis 2013; 56:1480-7.
15. Webster DP, Wojcikiewicz T, Keller M, et al. Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin. Int J STD AIDS 2013; 24: 179-83.
16. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351:451-9.
17. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIVinfected patients. N Engl J Med 2004; 351:438-50.
18. Fierer DS, Uriel AJ, Carriero DC, et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis 2008; 198:683-6.
19. Fierer DS, Mullen MP, Dieterich DT, Fiel MI, Branch AD. Early-onset liver fibrosis due to primary hepatitis C virus infection is higher over time in HIV-infected men. Clin Infect Dis 2012; 55:887-8.
20. Fierer DS, Dieterich DT, Fiel MI, et al. Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis 2013; 56:1038-43.
21. Bottieau E, Apers L, Van Esbroeck M, Vandenbruaene M, Florence E. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009. Euro Surveill 2010; 15:19673.
22. Cox AL, Page K, Bruneau J, et al. Rare birds in North America: acute hepatitis C cohorts. Gastroenterology 2009; 136:26-31.
23. Fierer DS, Khudyakov Y, Hare B, et al. Molecular epidemiology of incident HCV infection in HIV-infected MSM in the US vs infections in Europe and Australia [abstract 112]. In: 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2011.
24. Fierer DS, Uriel AJ, Carriero DC, et al. Sexual transmission of hepatitis C virus (HCV) among HIV-infected men who have sex with men (MSM), New York City, 2005-2010. JAMA 2011; 306:1194-6.
25. Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents. Hepatology 2012; 56:2398-403.
26. Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012; 55:1048-57.
27. Lontok E, Mani N, Harrington PR, Miller V. Closing in on the target: sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy. Clin Infect Dis 2013; 56:1466-70.
28. Burke CC, Martel-Laferriere V, Dieterich DT. Septic bursitis, a potential complication of protease inhibitor use in hepatitis C virus. Clin Infect Dis 2013; 56:1507-8.
29. Vogel M, Bieniek B, Jessen H, et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat 2005; 12:207-11.
30. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159:86-96.
31. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360:1827-38.
32. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-24.
33. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
34. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
35. Beinhardt S, Aberle JH, Strasser M, et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 2012; 142:78-85.e2.
36. Deterding K, Gruner N, Buggisch P, et al. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 2013; 13:497-506.
37. Grebely J, Hellard M, Applegate T, et al. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS 2012; 26:1653-61.
38. Nattermann J, Vogel M, Nischalke HD, et al. Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIVpositive patients with acute and chronic hepatitis C. J Infect Dis 2011; 203:595-601.
39. Grebely J, Feld JJ, Applegate T, et al. Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology 2013; 57:2124-34.
40. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5:e11068.
41. Martin NK, Vickerman P, Grebely J, et al. HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals [epub 28 March]. Hepatology 2013. doi:10.1002/hep. 26431.